Skip to content

Muti-omics Characterization of Patients with Omicron

Muti-omics Characterization of Patients with Omicron

Status
Active, not recruiting
Phases
Early Phase 1
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2200060068
Enrollment
Unknown
Registered
2022-05-17
Start date
2022-05-20
Completion date
Unknown
Last updated
2024-04-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Novel Coronavirus Pneumonia (COVID-19)

Interventions

Case series:None

Sponsors

Zhongshan Hospital, Fudan University
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1. Serum, plasma (heparin lithium, EDTA), urine and throat swab samples are kept in patients with novel coronavirus pneumonia and general fever patients, and the collection, processing and storage of the samples comply with the instructions; 2. Complete sample information, clear identification, traceable to the original record; 3. Inpatients of Zhongshan Hospital Affiliated to Fudan University and Geriatrics Center; 4. Informed consent for multi-omics study of Omicron COVID-19 infected patients should be signed; 5. Patients without underlying diseases are preferentially enrolled. Patients with common chronic diseases, such as hypertension, diabetes and cardiovascular diseases, can be enrolled.

Exclusion criteria

Exclusion criteria: 1. Samples with severe jaundice, turbidity, lipemia and hemolysis should be excluded; 2. Sample is insufficient, or contaminated, or sample information cannot be clearly identified; 3. The patient had a history of long-term drug use before admission, except for chronic diseases; 4. The patient has a history of malignancy.

Design outcomes

Primary

MeasureTime frame
proteomics;metabolomics;whole genome sequencing;

Countries

China

Contacts

Public ContactGuo Wei, Fang Hao
guo.wei@zs-hospital.sh.cn+86 21 6404 1990

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026